skip to Main Content

PEGPH20 Could Improve Metastatic Pancreatic Cancer Outcomes

Newsfeed image, light gray text on dark gray background
Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma, according to a new study.

Hyaluronan (HA) is a naturally occurring polysaccharide. “HA is secreted in excessive amounts in many pancreas cancers into the interstitium,” said Sunil R. Hingorani, MD, PhD, of the Fred Hutchinson Cancer Research Center in Seattle. PEGPH20, a pegylated form of recombinant human hyaluronidase PH20, has been shown in preclinical studies to degrade intratumoral HA. The subsequent decrease in fluid pressures can improve blood flow, allowing better drug delivery to the tumor bed. Read more . . .

Back To Top